Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $547.62, for a total value of $5,202,390.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at $22,185,729.06. The trade was a 19.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Trading Down 0.9%

Shares of NASDAQ UTHR traded down $5.18 during trading hours on Monday, reaching $544.69. The stock had a trading volume of 431,236 shares, compared to its average volume of 480,455. The firm has a market cap of $23.12 billion, a price-to-earnings ratio of 20.11, a P/E/G ratio of 1.79 and a beta of 0.57. The business’s fifty day moving average price is $568.23 and its two-hundred day moving average price is $519.16. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.63 EPS. Equities research analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of research reports. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. UBS Group upped their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $619.42.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently made changes to their positions in the business. Arjuna Capital increased its position in shares of United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after purchasing an additional 18 shares in the last quarter. Clearstead Advisors LLC increased its position in shares of United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 23 shares in the last quarter. Sage Rhino Capital LLC increased its position in shares of United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC increased its position in shares of United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 24 shares in the last quarter. Finally, Meeder Advisory Services Inc. increased its position in shares of United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after purchasing an additional 26 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.